Fat necrosis of breast

Summary

Fat necrosis of breast (MONDO:0001101) is a disease and 1 clinical trial. A subtype of breast disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	fat necrosis of breast
Mondo ID	MONDO:0001101
DOID	DOID:10691
ICD-10-CM	N64.1
ICD-11	149925294
NCIT	C3661
SNOMED CT	21381006
UMLS	C0156321
MedGen	57847
Is cancer (heuristic)	no

Also known as: breast fat necrosis · fat Necrosis of the breast

Disease family

This is a subtype of breast disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › breast disorder › fat necrosis of breast

Related subtypes (14): breast abscess, hypertrophy of breast, breast angiomatosis, breast adenosis, benign mammary dysplasia, breast fibrocystic disease, mastitis, familial juvenile hypertrophy of the breast, supernumerary breasts, isolated congenital breast hypoplasia/aplasia, syndromic breast hypoplasia/aplasia, breast neoplasm, lactation disease, breast implant illness

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02583607	PHASE1/PHASE2	UNKNOWN	Brava and Fat Transfer for Breast Reconstruction